Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System

Transapical Implantation of a Percutaneous Aortic Tissue Valve Validates Trinity's Technology

REGENSBURG, Germany, September 16, 2010 - Transcatheter Technologies GmbH (TT), an innovative medical device
company that is developing a second-generation transcatheter aortic valve
prosthesis, announced today that its proprietary transapical aortic valve has
been successfully implanted in the acute porcine model.

The acute in vivo study of the Trinity system has shown:

    1) Accurate stepwise positioning of Trinity via an antegrade transapical
       approach.

    2) Full expansion and anchoring of the Trinity valve prosthesis before
       the refolding of the stent.

    3) Complete evaluation of the fully expanded prosthesis' function before
       refolding and repositioning or retrieval.

    4) Detachment of the stent from the catheter without changing the
       geometry of the deployed valve prosthesis.

    5) Outstanding anchoring and sealing due to the unique design of the
       stent.

    6) Low transvalvular gradients.

TT's unique true repositioning system allows for complete expansion of
the valved stent and full evaluation of prosthesis' function before
repositioning, before retrieval, and before final release.

"Our aim is to remove the risks and anxiety associated with current
transcatheter valve implantation procedures. Trinity's true repositioning
technology allows the user to fully expand and anchor the valve, then
evaluate hemodynamic valve function before separating from the catheter,"
said Hou-Sen Lim, CTO. "Our proprietary pre-mounted valve technology removes
the need to mount the valve onto the catheter system in the operating room
prior to the procedure, thereby reducing the cost and eliminating the risk
associated with mounting the valve by an assistant at the implantation side."

"Trinity protects the fragile valve leaflets by Zero Pressure Crimping.
This prevents crushing and damaging of the leaflets when the frame is folded.
We expect that this will increase the lifespan of the valve prosthesis and
thereby allowing for implantation in even younger patients," commented
Wolfgang Goetz MD, PhD, CEO. "Our animal trials validate the feasibility of
the technology in vivo. We are very proud to have achieved this significant
milestone within a very short period of time."

Transcatheter Technologies successful closed the seed financing round in
2009 with High-Tech Gründerfonds and Seedfonds Bayern. The investment will be
used for the development of a novel biological heart valve up to the proof of
concept. "Transcatheter Technologies' valve design can solve major problems
of common prosthesis. Thereby, valve implantations become an option for
currently untreatable patients. We are convinced that the medicinal as well
as technological expertise of the team provide an ideal base for a successful
corporate development", adds Dr. Michael Nettersheim from High-Tech
Gründerfonds.

About Transcatheter Technologies GmbH

Transcatheter Technologies GmbH is a privately held medical device
company, founded in January 2009, and headquartered in Regensburg, Germany.
The Trinity transapical aortic valve system's valve prosthesis is premounted
on the catheter. Trinity's unique features enable true repositioning and Zero
Pressure Crimping, which improve valve durability and broaden the scope of
application of transcatheter valve implantations across a larger patient
population. Trinity valve prosthesis is comprised of a bovine pericardium
valve that is mounted on a self-expanding nitinol frame. Its implantation is
performed transapically on a beating heart without the need for open-heart
surgery.

For more information, contact Wolfgang Goetz, MD, PhD, CEO
(wolfgang.goetz@transcatheter-technologies.com) or Hou-Sen Lim, MEng, CTO,
(hou-sen.lim@transcatheter-technologies.com), Transcatheter Technologies
GmbH, BioPark Regensburg, Josef-Engert-Str. 11, 93053 Regensburg, Germany,
+49-170-6309920/21.

About High-Tech Gründerfonds

High-Tech Gründerfonds invests risk capital in young, high-potential
technology companies that convert promising research results in business
success. The seed finance provided aims to enable start-ups to take their R&D
project through to the creation of a prototype, a proof of concept or to
market launch. Investors in this public/private partnership are the German
Federal Ministry for Business and Technology, the KfW Banking Group as well
as the six industrial groups of BASF, Deutsche Telekom, Siemens, Robert
Bosch, Daimler and Carl Zeiss. High-Tech Gründerfonds has a fund volume of
about 272 million euros.

For more information, contact Dr. Michael Nettersheim, Senior
Investmentmanager, High-Tech Gründerfonds Management GmbH,
Ludwig-Erhard-Allee 2, 53175 Bonn, Germany,
Phone:+49-228-96568500,Fax: +49-228-96568550,
www.high-tech-gruenderfonds.de.

For more information, contact Wolfgang Goetz, MD, PhD, CEO (wolfgang.goetz at transcatheter-technologies.com) or Hou-Sen Lim, MEng, CTO, (hou-sen.lim at transcatheter-technologies.com), Transcatheter Technologies GmbH, BioPark Regensburg, Josef-Engert-Str. 11, 93053 Regensburg, Germany, +49-170-6309920/21. For more information, contact Dr. Michael Nettersheim, Senior Investmentmanager, High-Tech Gründerfonds Management GmbH, Ludwig-Erhard-Allee 2, 53175 Bonn, Germany, Phone:+49-228-96568500,Fax: +49-228-96568550, www.high-tech-gruenderfonds.de.